申请人:ONTOGEN CORPORATION
公开号:EP0812830A1
公开(公告)日:1997-12-17
The present invention relates to imidazole derivatives having formula 1
wherein:
R1 is selected from the group consisting of:
mono-,di-,and tri-substituted phenyl or thienyl, the substituents are selected from the group consisting of:
(i) substituted C1-6 alkyl, substituted C2-6 alkyloxy, wherein the substituents are selected from the group consisting of hydrogen or C1-6 alkoxy;
(ii) C1-11CO2R5, trans- CH=CHCO2R5, wherein R5 is C1-11 alkyl, or phenyl C1-11 alkyl;
R2 and R3 are mono-, di, and tri-substituted phenyl wherein the substituents are independently selected from:
(i) halo;
(ii) C1-6 alkyl-amino, or di(C1-6 alkyl)amino, and R4 is hydrogen.
These compounds are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents.
本发明涉及具有式 1 的咪唑衍生物
其中
R1 选自以下组成的组
单、二和三取代的苯基或噻吩基,取代基选自由以下组成的组
(i) 取代的 C1-6 烷基、取代的 C2-6 烷氧基,其中取代基选自由氢或 C1-6 烷氧基组成的组;
(ii) C1-11CO2R5、反式-CH=CHCO2R5,其中 R5 为 C1-11 烷基或苯基 C1-11 烷基;
R2 和 R3 是单取代、二取代和三取代苯基,其中取代基独立选自
(i) 卤
(ii) C1-6 烷基氨基或二(C1-6 烷基)氨基,R4 为氢。
这些化合物可用于恢复耐多药细胞对癌症化疗药物的敏感性。